Seagen Inc.

SGEN

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase3 readout (tucatinib): Jun 2023.

BiotechnologyCEO: David R. EpsteinIPO: 2001Website ↗

Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.

Catalysts

Phase 3Q2 2023tucatinibHER2-positive Breast CancerNCT03975647

Primary: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months))Enrollment:466/466Sites: 490RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2023tucatinibUterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract NeoplasmsNCT04579380

Primary: Confirmed Objective Response Rate (cORR) as Assessed by Investigator (From the first dose of study treatment until the first documented CR or PR on or before the first documented PD or new anti-cancer therapies or death, whichever occurred first (up to 28.3 months))Enrollment:217/217Sites: 108NA, TREATMENT

Phase 2Q3 2024tucatinibColorectal Carcinoma, Gastric Adenocarcinoma, GEJ AdenocarcinomaNCT04430738

Primary: Number of Participants With Renal Dose-Limiting Toxicities (DLTs): Phase 1b (Cohort 1A and 1B) (From first dose of tucatinib until end of Cycle 3 (up to 42 days))Enrollment:40/40Sites: 27NON_RANDOMIZED, TREATMENT

Phase 3Q3 2025TucatinibHER2 Positive Breast CancerNCT05132582

Primary: Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years)Enrollment:654/654Sites: 307RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026Brentuximab vedotinDiffuse Large B-cell LymphomaNCT04404283

Primary: Overall survival (OS) (Approximately 2 years)Enrollment:239/239Sites: 143RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2026tisotumab vedotinColorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic CancerNCT03485209

Primary: Confirmed Objective Response Rate (ORR) (Parts A, B, C, D, E, F, and G) (Up to approximately 3 years)Enrollment:350/350Sites: 175NON_RANDOMIZED, TREATMENT

Phase 3Q2 2026tucatinibColorectal NeoplasmsNCT05253651

Primary: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR) (Up to approximately 3 years)Enrollment:Target 400Sites: 366RANDOMIZED, TREATMENT

Phase 3Q2 2026sigvotatug vedotinCarcinoma, Non-Small-Cell LungNCT06012435

Primary: Overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel) (Approximately 5 years)Enrollment:762/762Sites: 331RANDOMIZED, TREATMENT

Phase 2Q2 2026disitamab vedotinCarcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial NeoplasmsNCT06003231

Primary: Confirmed Objective Response Rate (ORR) per Response Evaluation in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment (Approximately 3 years)Enrollment:120/120Sites: 96NA, TREATMENT

Phase 2Q4 2026disitamab vedotinUrothelial CarcinomaNCT04879329

Primary: Confirmed Objective Response Rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) by blinded independent central review (BICR) (Cohorts A, B, C, and G) (Duration of treatment; approximately 2 years)Enrollment:Target 372Sites: 221RANDOMIZED, TREATMENT

Phase 3Q1 2027disitamab vedotinUrothelial CarcinomaNCT05911295

Primary: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR) (Approximately 3 years)Enrollment:412/412Sites: 268RANDOMIZED, TREATMENT

Phase 2Q3 2029disitamab vedotinBreast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast NeoplasmsNCT06157892

Recent News & Research

PubMed

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.

# Investment Summary: Seagen Brentuximab Vedotin Study **Clinical Finding:** This multicenter cohort study demonstrates that brentuximab vedotin-containing regimens achieve superior efficacy and comparable safety profiles to standard chemotherapy in relapsed/refractory Hodgkin lymphoma (R/R HL), supporting the drug's established role in this heavily-treated population. **Commercial Implication:** The data reinforce brentuximab vedotin's clinical utility and competitive positioning in R/R HL, a key indication for Seagen's commercial portfolio, though the 2026 publication date suggests this validates rather than introduces new evidence for an already-marketed therapeutic. **Investor Note:** Results are clinically supportive but likely incremental; impact depends on whether findings influence treatment guidelines, payer reimbursement decisions, or expand eligible patient populations in a market already established for this

Dec 31, 2026

PubMed

Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.

I don't have access to the specific article you're referencing (published October 2026), so I cannot provide an accurate summary of its contents or clinical findings. To give you a meaningful analysis for SGEN investment purposes, I would need either: - The article text or abstract - Specific data points discussed (efficacy rates, patient populations, competitive positioning) - Details on how treatment algorithms evolved and which agents were emphasized If you can share the abstract or key findings, I can quickly synthesize the clinical/commercial implications for Seagen's HER2-directed portfolio (trastuzumab deruxtecan, etc.) and assess relevance to market positioning or label expansion opportunities.

Oct 8, 2026

PubMed

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.

# Investment Summary: Disitamab Vedotin + Tislelizumab in NMIBC **Clinical Finding:** A Chinese trial demonstrated efficacy of disitamab vedotin (an HER2-targeted ADC) combined with tislelizumab (anti-PD-1) in transurethrally unresectable, HER2-positive non-muscle-invasive bladder cancer (NMIBC), addressing a patient population with limited treatment options beyond radical cystectomy. **Investment Implication:** While this data supports the commercial potential of HER2-targeted ADCs in NMIBC—a historically underpenetrated indication—the non-randomized design limits regulatory impact. For Seagen investors, this validates the broader ADC+checkpoint inhibitor combination strategy in solid tumors, though direct competitive relevance depends on Seagen's NMIBC pipeline positioning

Oct 8, 2026

PubMed

Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group.

# Seagen Investment Summary I cannot provide an accurate summary of this article because the publication date (October 2026) is in the future, making this a fictional or incorrectly dated reference that I cannot verify. **What I can offer instead:** If you're tracking Seagen's clinical pipeline, I'd recommend: - Verifying the correct publication date and journal citation - Checking Seagen's official pipeline disclosures for disitamab vedotin (if in development) - Reviewing actual clinical trial results from ClinicalTrials.gov or company press releases For urothelial carcinoma ADC programs specifically, investors should focus on: efficacy/safety data versus standard-of-care, market size (estimated 80K+ annual US cases), and competitive positioning against other ADCs in this indication. Please resubmit with the correct publication details, and I'll provide a detailed

Oct 7, 2026

PubMed

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma.

# Summary for SGEN Investors This study demonstrates sustained efficacy of brentuximab vedotin (Adcetris) combined with chemotherapy and radiation in early-stage unfavorable Hodgkin lymphoma at five-year follow-up, supporting the drug's role as a standard-of-care component in this population. The long-term data strengthen the clinical evidence base for Adcetris in front-line treatment, potentially supporting label expansion and maintaining market position despite generic/biosimilar competition risks in later years. For SGEN, this validates the durability of one of its core revenue drivers in lymphoma, though investors should monitor upcoming head-to-head comparisons with newer checkpoint inhibitors and antibody-drug conjugate combinations that may reshape treatment paradigms.

Oct 1, 2026

Seagen Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research